Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.64 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 4/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520474 | 0.90 | ATAD2 (0.53) | ATAD2CYP11B2CYP11B1CYP1A2CYP17A1 | |
| SCHEMBL496099 | 0.86 | ATAD2 (0.51) | ATAD2CYP11B2CYP11B1CYP1A2CYP17A1 | |
| Hydrochloric Acid SCHEMBL3597662 | 0.84 | ATAD2 (0.50) | ATAD2CYP11B2CYP11B1CYP1A2CYP17A1 | |
| SCHEMBL520157 | 0.84 | TRIM24 (0.49) | ATAD2TRIM24 | |
| SCHEMBL5506946 | 0.82 | TRIM24 (0.48) | ATAD2TRIM24 | |
| SCHEMBL422074 | 0.80 | SRD5A1 (0.58) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL16453538 | 0.79 | ATAD2 (0.78) | ATAD2CYP11B2CYP11B1CYP1A2CYP19A1 | |
| SCHEMBL3591114 | 0.79 | CYP11B2 (0.51) | ATAD2CYP11B2CYP11B1CYP1A2CYP17A1 | |
| SCHEMBL6073575 | 0.79 | CYP11B2 (0.51) | CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL5543650 | 0.79 | CYP11B2 (0.51) | ATAD2CYP11B2CYP11B1CYP1A2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025096710-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025076470-A1 | SOX10 INHIBITORS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119019369-A | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240343707-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE | 2024-10-17 | — | — | US | disclosed |
| CN-115397821-B | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1478629-B1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN CO LLC (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005082897-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-09-09 | — | — | WO | disclosed |
| US-6919329-B2 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1478629-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
| WO-2003072553-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-1049692-A1 | NOVEL BICYCLENE-SUBSTITUTED OXAZOLIDINONES | Bayer Aktiengesellschaft (DE) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037641-A1 | NOVEL BICYCLENE-SUBSTITUTED OXAZOLIDINONES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | ATAD2 200/4885CYP11B2 2413/4885CYP11B1 3456/4885 |
| US-20240343707-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | PRNP, PNP, ZC3HAV1 | ATAD2 2448/4885CYP11B2 3691/4885CYP11B1 3464/4885 |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | ATAD2 1013/4885CYP11B2 3989/4885CYP11B1 4250/4885 |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | ATAD2 200/4885CYP11B2 2413/4885CYP11B1 3456/4885 |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PAH, ALDH2, IDH2 | ATAD2 1349/4885CYP11B2 19/4885CYP11B1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.